TuHURA Biosciences Net Profit Margin 2010-2024 | HURA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

TuHURA Biosciences net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

TuHURA Biosciences net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.8B
Vertex Pharmaceuticals (VRTX)	$122.6B
Gilead Sciences (GILD)	$109.8B
Bristol Myers Squibb (BMY)	$107B
Regeneron Pharmaceuticals (REGN)	$106.1B
CSL (CSLLY)	$96.1B
GSK (GSK)	$78.8B
Alnylam Pharmaceuticals (ALNY)	$38.1B
Argenex SE (ARGX)	$34B
Biogen (BIIB)	$27.1B
BioNTech SE (BNTX)	$26.4B
Illumina (ILMN)	$22.9B
BeiGene (BGNE)	$21.5B
Moderna (MRNA)	$20.5B
Genmab (GMAB)	$15.1B
BioMarin Pharmaceutical (BMRN)	$13.4B
Exact Sciences (EXAS)	$13B
Insmed (INSM)	$12.7B
Incyte (INCY)	$12.6B
Vaxcyte (PCVX)	$12.6B
Sarepta Therapeutics (SRPT)	$12.2B
Bio-Techne Corp (TECH)	$11.1B
QIAGEN (QGEN)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.3B
Roivant Sciences (ROIV)	$8.7B
Exelixis (EXEL)	$8.2B
Legend Biotech (LEGN)	$8.2B
Intra-Cellular Therapies (ITCI)	$8.1B
Repligen (RGEN)	$8.1B
Revolution Medicines (RVMD)	$7.9B